World Alzheimer’s Day: Sant Pau Focuses on Individuals with Down Syndrome

On World Alzheimer’s Day, the aim is to raise awareness about this incurable neurodegenerative disease that primarily affects elderly individuals. However, this year, Hospital de Sant Pau has shifted its attention to a particularly vulnerable group: individuals with Down syndrome. Alzheimer’s is characterized by cognitive decline and behavioral disturbances, with recent memory loss being one … Read more

Why study sex differences in Alzheimer’s disease and in the context of Down syndrome?

Why study sex differences in Alzheimer’s disease and in the context of Down syndrome?

Why study sex differences in Alzheimer’s disease and in the context of Down syndrome? The topic of sex differences is increasingly recognized as a top priority in neurology research, particularly in the context of precision medicine and personalized care strategies. Women account for around two-thirds of patients with Alzheimer’s disease, as well as their caregivers. … Read more

The effect of different preanalytical conditions on the stability of blood biomarkers in the diagnosis of Alzheimer’s disease

Clin Chem Lab Med - Mansilla et al. 2023

Stability of plasma samples and Alzheimer’s biomarkers Alzheimer’s disease is considered one of the most common causes of dementia in the elderly. Recently, blood biomarkers: Aβ1-42, Aβ1-40 and phospho Tau181 (p-Tau181), are proving useful in the diagnosis of the disease in research studies, but their analytical stability is unknown. A joint study between the Memory … Read more

GFAP in plasma and CSF in Down syndrome and Alzheimer’s disease

gfap - Sant Pau Memory Unit - Montoliu-Gaia - Alcolea

Alzheimer’s Disease, Down Syndrome and GFAP People with Down syndrome are at higher risk of developing Alzheimer’s disease than the general population. In fact, by the age of 70, more than 95% of people with Down syndrome will develop Alzheimer’s disease, which is the leading cause of death in this population. This strong association is … Read more

Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist

blood-based biomarkers in neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, are a growing health concern worldwide, and their diagnosis and management are still challenging. However, recent advances in blood-based biomarkers offer new opportunities for clinical evaluation and monitoring of these diseases. In this review article, entitled “Blood Biomarkers in Neurodegenerative Diseases: Implications for the … Read more

Multimarker synaptic panels for FTD

Multimarker panels in FTD Frontotemporal dementia is the most common cause of early-onset dementia and the principal cause of FrontoTemporal Lobular Degeneration (FTLD). Approximately, 90–95% of FTLD cases are characterized by the accumulation in the brain of two different proteins – tau and transactive response DNA-binding protein-43 (TDP-43). These protein inclusions lead to a loss of … Read more